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Comments have frequently been made about the changes 
occurring in medical practice in the era of prospective 
payment. An excellent example of the new environment in 
which we practice is the recent controversy surrounding the 
reimbursement for thrombolytic therapy of acute mvocardial 
infarction, particularly tissue plasmi&gen activatdr it-PA). 
The issue remains unresolved. and addition:! d::a will likely 
be required before a final determination is reached. How- 
ever, the reimbursement for t-PA therapy of acute myocar- 
dial infarction exemplifies many of the issues that cardiovas- 
cular specialists will have to address in the future. 
Issuer ofdata and interpretation. With thrombolytic ther- 
apy, as with many unresolved issues, some data appear 
established. there is disagreement regarding the interpreta- 
tion of some facts and still other data are awaited. Some 
facts are quite clear at present. Several studies have docu- 
mented that thrombolytic therapy in patients with acute 
myocardial infarction is highly successful in recanalieing the 
occluded vessel and in reducing mortality. Two agents are 
currently approved for this application, streptoki&e and 
I-PA. Strong data exist to document the reduction in mor- 
tality obtained with streptokinase, whereas similar data as 
compared with control are just now being brought forth with 
regard to t-PA. Randomized comparisons of these two 
agents demonstrated that t-PA has a higher recanalization 
rate than does streptokinase. especbdlv when it is adminis- 
tered >3 h after the onset of rymptom~. However, B differ- 
ence in mortality was not demonstrated. Some physicians 
have interpreted these findings to indicate that the higher 
rate of vessel patency obtained with t-PA than with strepto- 
kinasc should lead to a superior reduction in monatity with 
t-PA. Of significance. recovery of left ventricular function 
and the complicalions and side effects of therapy have been 
roughly equivalent with the two agents. 
Issues of cost effectiveness. A variety of relevant data 
addressing the issue of cost effectiveness are also available. 
At present. the cost of a dose oi streptokinase is approxi- 
mately %2M). whereas the cost of B dose of t-PA is approxi- 
mately S2.300. For comparison. the total reimbursement to 
hospitals for Medicare patients in urban hospitals covered bv 
the’diagnosi~.related >ooup (DRG) categokes dealing with 
acute myocardial infarction ranges from approximately 
$3.800 to $5.500 (mean $4.400). Finally. recent data from the 
University of Michigan sugggest hat lytic therapy may permit 
a reduction of hospital stay. with concomitant financial 
savings, in some patients with low risk myocardial infarc- 
tion. 
The cost of t-PA is approximately 45% of the mean DRG 
reimbursement to hospitals, and even streptokinase may 
represent nearly 5% of the DRG payment before pharmacy 
markup. Therefore, the American Hospital Asso&tion re- 
quested an increase in reimbursement for treatment with 
L-PA. either by creation of a new DRG category or by an 
increase in reimbursement for existing DRG categories for 
myocardial inhrction. This issue was referred to the Pm- 
spective Payment Commission (PROPACI. whosejob it is to 
make recommendations rccardine. aporooriate reimburse- 
ments for the Me*‘care p&p&e t&&t systan. Atier 
consideration. PROPAC concluded that a consensus among 
physicians did not exist regarding the superiority of t-PA 
over streptokinase, and took note of the difference in cost. 
This commission then recommended a compromise: the 
addition of a sum of money to the DRG pool equivalent to 
the mean cost of t-PA and streptokinase (approximately 
%l.ZOOl for each potential Medicare beneficiary who would 
qualify for thmmbolytic therapy. This recommendation was 
taken under consideration by William Roper, MD, Admin- 
istrator of the Health Care Financing Administration, and 
later bv Otis Bowen. MD. Secretary oi Health and Human eral lcc~onc can be learned. Now that prosoective pwment 
Se&s. These individuals ultima& decided the! no \pe- 
cilic cast-based add-on to the DRG syslcm would be made 
for the use of t-PA but rather that reimbursement ior 
thrombolytic lherapy would become a ixtor in the routine 
rer4ibntion ofthe DRG system scheduled to be undertaken 
each year. A major reason cited ior this decision wa\ the 
potentuS for cost savings as a result of possible reduction of 
hospitalization secondary to treiltmrnt with thrombolytic 
therapy. 
Al present. no alterations have been made in the Mcdi- 
care pmspeclive payment system to accommodate the addi- 
tional costs associated with thrombolytic therapy. Hospitals 
can be compensated by Medicare for L-PA costs when Ihe 
drug is given to an outpalient but nol 10 an inparicnt. 
Recalibration of DRGs will be performed in October 1988 
and will be based on data from calendar year 19X7. much of 
which antedates the availability of t-PA. D&I defining the 
comparative effects of various thrombolylic agents on over- 
all monalily will require large randomized prospective wd- 
ies and will take years to perform. Likewise. csrciully 
controlled studies on reduction of in-ho\pit;tl stay will prob- 
ably not be available in the near future. The impact of 
lhrombolytic therapy on cardiac calheteriwtion. coronary 
angioplasty and coronary bypass surgery during hospilaliza- 
tion will also need to be addressed. 
Future prospeetr. From this recouming of the d&Is of 
the deliberations regarding reimbwsemcnt for thrombolylic 
therapy of awe myocardial inhrcdon. it appeen that sev- 
is in pkce. alwalions in M.edicare rei~bu&enr‘idr new 
lechnology will likely require a rurtained process oiinlerac- 
non wdh povernmenl agencies. This prow>> demands iha 
rhe rcience supporting the efficacy of ihe new technology he 
\ccurc and definitive. lo this regard. it is likely that phyri- 
ciao\ will hwe to he nearly unanimous in their support of the 
benefit oilhc new approach. In addition. it is clear lhal new 
technology will be carefully examined in terms of cost 
cfiicacy in relation to other existing modalities. Consider- 
ation wi!l be @en not only to which therapy is better. but to 
how much better and at what price. It now seems certain that 
the co*1 adjuslmcnt appropriate for any new medica: rech- 
nology will be delenoined with reference to all oi the 
ah~n~tion~ and e’tpenditures that result from the new pnc- 
lice. WC an therefore expect that requests for increased 
reimbuncmcm from the ~ovemment \pi!l require an analysis 
of the implications oi the new technology on both cost 
savings and lolaI expenses. Finally. the optimal mechanism 
by which allcmtions and reimburrcment are to oe imple- 
mewed-th;u is. a new. a revised. or a recalibrated DRG- 
$41 continue to be a source of debate. 
A* is evident from the experience with I-PA. we are livin$ 
in ii period oi sub~lanlial change in both Ihe type of medical 
care we provide and Ihe way in which il is delivered and 
reimburwd. Our ability to continue the advances in card& 
vascok~r medicine will he dependent on our ability to address 
the i’i\ucs presenled by Ihe new environment. 
